Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ESLA

Estrella Immunopharma Inc

Last Close
Sep 19 02:43PM ET
0.9650
Dollar change
+0.0350
Percentage change
3.77
%
Index- P/E- EPS (ttm)-0.18 Insider Own75.60% Shs Outstand36.38M Perf Week-18.22%
Market Cap35.11M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.88M Perf Month-30.07%
Income-0.63M PEG- EPS next Q- Inst Own0.34% Short Float0.22% Perf Quarter9.66%
Sales0.00M P/S- EPS this Y- Inst Trans0.09% Short Ratio0.21 Perf Half Y-7.22%
Book/sh0.23 P/B4.15 EPS next Y- ROA-2.28% Short Interest0.02M Perf Year-90.04%
Cash/sh0.13 P/C7.42 EPS next 5Y- ROE-2.51% 52W Range0.81 - 20.80 Perf YTD-13.06%
Dividend Est.- P/FCF- EPS past 5Y- ROI-7.47% 52W High-95.36% Beta0.22
Dividend TTM- Quick Ratio62.34 Sales past 5Y- Gross Margin- 52W Low19.14% ATR (14)0.16
Dividend Ex-Date- Current Ratio62.34 EPS Y/Y TTM-44.10% Oper. Margin0.00% RSI (14)40.88 Volatility17.28% 13.20%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q51.47% Payout- Rel Volume0.08 Prev Close0.93
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume95.25K Price0.97
SMA20-13.92% SMA50-28.25% SMA200-16.85% Trades Volume6,281 Change3.77%
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Emeryville, CA.